

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EU578409176US, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: January 28, 2003

Signature: *Ronnie Webb*
(Ronnie Webb)

Docket No.: HO-P02373US1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

P#7

In re Patent Application of:
Rong-Fu Wang

Application No.: 10/077,555

Group Art Unit: 1645

Filed: February 15, 2002

Examiner: Not Yet Assigned

For: USE OF CELL-PENETRATING PEPTIDES
TO GENERATE ANTITUMOR IMMUNITY

TECH CENTER 1600/2900
JAN 30 2003

RECEIVED

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
Washington, DC 20231

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned.

A copy of each reference on PTO/SB/08 is attached.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. It is submitted that the Information

Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. HO-P02373US1.

Dated: January 28, 2003

Respectfully submitted,

By 

Melissa L. Sistrunk

Registration No.: 45,579

FULBRIGHT & JAWORSKI L.L.P.

1301 McKinney, Suite 5100

Houston, Texas 77010-3095

(713) 651-5151

(713) 651-5246 (Fax)



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
Sheet	1	of	2	Application Number	10/077,555
				Filing Date	February 15, 2002
				First Named Inventor	Rong-Fu Wang
				Art Unit	1645
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	HO-P02373US1

TECH CENTER 1600/2003
JAN 30 2003

RECEIVED

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear


FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
BA	IB-98/46083-A1		10/22/1998	The Regents of the University of California	T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹Applicant's unique citation designation number (optional). ²See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	CA	Banchereau, Jacques, et al.; Dendritic cells and the control of immunity; Nature, Vol. 392, pp 245 - 252, March 19, 1998			
	CB	Bellone, Matteo, et al.; Relevance of the Tumor Antigen in the Validation of Three Vaccination Strategies for Melanoma; The Journal of Immunology, 2000, 165:2651 - 2656			
	CC	Cella, Marina, et al.; Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells; Nature, Vol. 388, pp 782 - 787, August 21, 1997			
	CD	Celluzzi, Christina M., et al.; Peptide-pulsed Dendritic Cells induce Antigen-specific, CTL-mediated Protective Tumor Immunity; J. Exp. Med., Vol. 183, pp 283 - 287, January 1996			
	CE	Dallal, Ramsey M., et al.; The dendritic cell and human cancer vaccines; Current Opinion in Immunology 2000, 12:583 - 588			
	CF	Houghton, Alan N., et al.; Immunity against cancer: lessons learned from melanoma; Current Opinion in Immunology, 2001, 13:134 - 140			
	CG	Gilboa, Eli; The Makings of a Tumor Rejection Antigen; Immunity, Vol. 11, pp 263 - 270, September 1999			
	CH	Ludewig, Burkhard, et al.; Role of dendritic cells in the induction and maintenance of autoimmune diseases; Immunological Reviews 1999, Vol. 169:45 - 54			
	CI	Mehta-Damani, Anita, et al.; Generation of Antigen-specific CD8+ CTLs from Naive Precursors; The Journal of Immunology, 1994, 153: 996 - 1003			
	CJ	Nestle, Frank O., et al.; Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells; Nature medicine, Vol. 4 (3), pp 328 - 332, March 1998			
	CK	Overwijk, Willem W., et al.; Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4+ T lymphocytes; Proc. Natl. Acad. Sci. USA (Immunology), Vol. 96, pp 2982 - 2987, March 1999			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
				Application Number	10/077,555
				Filing Date	February 15, 2002
				First Named Inventor	Rong-Fu Wang
				Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	HO-P02373US1


RECEIVED
JAN 30 2003
CH CENTER 1600/2000

	CL	Paglia, Paola, et al.; Murine Dendritic Cells Loaded In Vitro with Soluble Protein Prime Cytotoxic T Lymphocytes against Tumor Antigen In Vivo; J. Exp. Med., Vol. 183, pp 317 - 322, January 1996
	CM	Schreurs, Marco W. J., et al.; Dendritic Cells Break Tolerance and Induce Protective Immunity against a Melanocyte Differentiation Antigen in an Autologous Melanoma Model; Cancer Research, Vol. 60, pp 6995 - 7001, December 15, 2000
	CN	Schuler, G., et al.; Commentary - Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors; J. Exp. Med., Vol. 186 (8), pp 1183 - 1187, October 20, 1997
	CO	Thurner, Beatrice, et al.; Vaccination with Mage-3A1 Peptide-pulsed Mature, Monocyte-derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma; J. Exp. Med., Vol. 190 (11), pp 1669 - 1678, December 6, 1999
	CP	Young, James W., et al.; Dendritic Cells as Adjuvants for Class I Major Histocompatibility Complex-restricted Antitumor Immunity; J. Exp. Med., Vol. 183, pp 7 - 11, January 1996
	CQ	Wang, Rong-Fu, et al.; Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells; Nature Biotechnology, Vol. 20, pp 149 - 154, February 2002
	CR	Wang, Rong-Fu, et al.; Human tumor antigens for cancer vaccine development; Immunological Reviews, Vol. 170:85 - 100, 1999

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



01-29-09

1645

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

6

Application Number	10/077,555
Filing Date	February 15, 2002
First Named Inventor	Rong-Fu Wang
Group Art Unit	1645
Examiner Name	Not Yet Assigned

TECH CENTER 1600/2900

JAN 30 2003

RECEIVED

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below)
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> IDS by Applicant Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	Copies of 19 references
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual Name	FULBRIGHT & JAWORSKI L.L.P. Melissa L. Sistrunk
Signature	
Date	January 28, 2003

Transmittal

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EU578409176US, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: January 28, 2003

Signature:

(Ronnie Webb)



Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EU578409176US in an envelope addressed to:

Commissioner for Patents
Washington, DC 20231

on January 28, 2003
Date

Ronnie Webb

Signature

Ronnie Webb
Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant

RECEIVED
JAN 30 2003
TECH CENTER 1600/2900